SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2183980

Cover Image

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2183980

Rapid Multiplex Infectious Disease Testing Market Forecasts to 2034 - Global Analysis By Product & Service, Test Type, Technology, Pathogen Type, Application, End User and By Geography

PUBLISHED:
PAGES: 300+ Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4150
PDF (2-5 User License)
USD 5250
PDF & Excel (Site License)
USD 6350
PDF & Excel (Global Site License)
USD 7500

Add to Cart

According to Stratistics MRC, the Global Rapid Multiplex Infectious Disease Testing Market is estimated at $4.2 billion in 2026 and is expected to reach $10.8 billion by 2034, growing at a CAGR of 12.5% during the forecast period. Rapid Multiplex Infectious Disease Testing utilizes advanced molecular diagnostics, multiplex polymerase chain reaction, and automated detection technologies to identify multiple infectious pathogens simultaneously from a single patient sample. Increasing prevalence of infectious diseases, growing demand for rapid diagnosis, and expanding adoption of syndromic testing are driving market growth. Technological advancements in sample-to-answer platforms, integrated assay cartridges, and point-of-care diagnostics are improving testing efficiency. Growing investment in antimicrobial stewardship, healthcare infrastructure, and infectious disease surveillance is creating opportunities across hospitals, diagnostic laboratories, and public health institutions.

Market Dynamics:

Driver:

Increasing demand for rapid pathogen identification and syndromic infectious disease testing

Increasing demand for rapid pathogen identification and syndromic infectious disease testing is driving adoption of multiplex diagnostic technologies. Healthcare providers increasingly utilize molecular panels to detect multiple viral, bacterial, and other infectious agents within a single testing workflow. Rapid identification supports timely clinical decisions, appropriate treatment selection, and infection prevention measures. Growing respiratory disease burden, expanding hospital diagnostic capabilities, and increasing awareness of antimicrobial stewardship encourage adoption. Advances in automated molecular platforms further strengthen market development.

Restraint:

High multiplex testing costs and limited reimbursement coverage

High multiplex testing costs and limited reimbursement coverage restrain adoption of rapid multiplex infectious disease testing. Advanced diagnostic platforms require specialized instruments, expensive assay cartridges, and ongoing maintenance expenditure. Broad pathogen panels may generate additional costs when comprehensive testing is unnecessary for particular clinical presentations. Differences in reimbursement policies and healthcare budgets complicate routine utilization. Limited laboratory infrastructure and trained personnel in resource-constrained settings create further barriers to widespread implementation.

Opportunity:

Expansion of decentralized multiplex testing and automated molecular diagnostic platforms

Expansion of decentralized multiplex testing and automated molecular diagnostic platforms presents significant growth opportunities. Compact instruments, integrated microfluidic systems, and simplified sample preparation enable rapid pathogen detection closer to patients. These technologies can support emergency departments, urgent care facilities, and smaller healthcare institutions. Increasing investment in point-of-care molecular diagnostics, respiratory surveillance, and syndromic testing encourages innovation. Growing demand for faster clinical decisions and automated diagnostic workflows supports broader commercialization.

Threat:

Competition from conventional diagnostic methods and evolving pathogen detection requirements

Competition from conventional diagnostic methods and evolving pathogen detection requirements poses significant challenges to rapid multiplex infectious disease testing. Traditional cultures, targeted molecular assays, and antigen-based tests remain established alternatives for specific clinical applications. Emerging pathogen variants and changing epidemiological patterns may require frequent panel updates and additional validation. Increasing regulatory scrutiny, reimbursement pressure, and concerns regarding unnecessary broad-panel testing can affect adoption. Manufacturers must demonstrate clinical utility, accuracy, and cost-effectiveness.

Covid-19 Impact:

The COVID-19 pandemic significantly increased demand for rapid molecular diagnostics and multiplex respiratory pathogen testing. Healthcare providers adopted assays capable of distinguishing SARS-CoV-2 from influenza and other respiratory infections presenting similar symptoms. Diagnostic manufacturers expanded testing capacity, automated platforms, and assay development activities. However, supply chain disruptions and reagent shortages affected laboratory operations. Following the pandemic, sustained interest in respiratory surveillance, diagnostic preparedness, and decentralized molecular testing continues to support market development.

The assay kits & reagents segment is expected to be the largest during the forecast period

The assay kits & reagents segment is expected to account for the largest market share during the forecast period due to recurring demand for multiplex diagnostic panels, amplification reagents, and sample preparation materials. Each testing procedure requires specialized consumables for pathogen identification and molecular analysis. Increasing diagnostic testing volumes, expanding syndromic panel utilization, and growing hospital laboratory adoption encourage consumption. Advances in assay multiplexing, reagent stability, and standardized molecular workflows strengthen segment growth across infectious disease applications.

The point-of-care & urgent care centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the point-of-care & urgent care centers segment is predicted to witness the highest growth rate due to increasing demand for rapid infectious disease diagnosis outside centralized laboratories. Compact molecular analyzers and automated multiplex assays enable healthcare professionals to identify pathogens during patient consultations. Growing adoption of decentralized healthcare, expanding urgent care networks, and increasing demand for timely treatment decisions encourage utilization. Advances in portable instrumentation and simplified testing workflows support segment growth.

Region with largest share:

During the forecast period, North America is expected to hold the largest share due to advanced diagnostic infrastructure, substantial healthcare expenditure, and extensive adoption of molecular infectious disease testing. The United States leads regional development through hospitals, reference laboratories, and diagnostic manufacturers implementing automated multiplex platforms. Increasing demand for respiratory pathogen testing, antimicrobial stewardship initiatives, and established reimbursement pathways encourage utilization. Technological innovation and partnerships between diagnostic companies and healthcare providers strengthen regional commercialization.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing infectious disease surveillance, and growing investment in molecular diagnostics. China, Japan, India, South Korea, and Australia are advancing laboratory testing capabilities and point-of-care diagnostic programs. Improving access to automated molecular platforms, increasing healthcare expenditure, and growing awareness of rapid pathogen identification encourage adoption. Government public health initiatives and collaborations between diagnostic manufacturers and healthcare institutions support regional growth.

Key players in the market

Some of the key players in the Rapid Multiplex Infectious Disease Testing Market include bioMerieux SA, F. Hoffmann-La Roche Ltd., QIAGEN N.V., Danaher Corporation, Abbott Laboratories, Becton, Dickinson and Company, DiaSorin S.p.A., QuidelOrtho Corporation, Thermo Fisher Scientific Inc., Seegene Inc., Hologic, Inc., Revvity, Inc., Applied BioCode, Inc., Molbio Diagnostics Pvt. Ltd., Bosch Healthcare Solutions GmbH, Mobidiag Oy, GenMark Diagnostics, Inc., and Co-Diagnostics, Inc.

Key Developments:

In October 2026, Seegene Inc. presented its next-generation syndromic PCR testing strategy at the LMCE 2026 conference in Seoul. The company highlighted multiplex molecular technologies designed to detect multiple respiratory viruses and bacteria simultaneously, supporting differential diagnosis, identification of coinfections, and improved infectious disease management.

In October 2026, bioMerieux SA received U.S. FDA 510(k) clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Vaginitis Panel. The development expands access to rapid molecular testing in decentralized healthcare settings and strengthens the company's portfolio of multiplex infectious disease diagnostic solutions.

In August 2026, QIAGEN N.V. received U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, designed to identify 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in approximately one hour. The development expands rapid syndromic testing capabilities for bloodstream infections and supports timely clinical decision-making.

Products & Services Covered:

  • Instruments & Analyzers
  • Assay Kits & Reagents
  • Consumables & Cartridges
  • Testing Services
  • Other Products & Services

Test Types Covered:

  • Syndromic Multiplex Panels
  • Targeted Multiplex Panels
  • Other Test Types

Technologies Covered:

  • Multiplex Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification
  • Microarray-Based Detection
  • Multiplex Immunoassays
  • Other Technologies

Pathogen Types Covered:

  • Viral Pathogens
  • Bacterial Pathogens
  • Fungal Pathogens
  • Parasitic Pathogens
  • Other Pathogen Types

Applications Covered:

  • Respiratory Infection Testing
  • Gastrointestinal Infection Testing
  • Bloodstream Infection & Sepsis Testing
  • Meningitis & Encephalitis Testing
  • Sexually Transmitted Infection Testing
  • Healthcare-Associated Infection Testing
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic & Reference Laboratories
  • Point-of-Care & Urgent Care Centers
  • Academic & Research Institutions
  • Public Health Laboratories
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Product Code: SMRC41811

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Rapid Multiplex Infectious Disease Testing Market, By Product & Service

  • 5.1 Instruments & Analyzers
  • 5.2 Assay Kits & Reagents
    • 5.2.1 Multiplex Test Panels
    • 5.2.2 Sample Preparation & Extraction Reagents
  • 5.3 Consumables & Cartridges
  • 5.4 Testing Services
  • 5.5 Other Products & Services

6 Global Rapid Multiplex Infectious Disease Testing Market, By Test Type

  • 6.1 Syndromic Multiplex Panels
  • 6.2 Targeted Multiplex Panels
  • 6.3 Other Test Types

7 Global Rapid Multiplex Infectious Disease Testing Market, By Technology

  • 7.1 Multiplex Polymerase Chain Reaction (PCR)
  • 7.2 Isothermal Nucleic Acid Amplification
  • 7.3 Microarray-Based Detection
  • 7.4 Multiplex Immunoassays
  • 7.5 Other Technologies

8 Global Rapid Multiplex Infectious Disease Testing Market, By Pathogen Type

  • 8.1 Viral Pathogens
  • 8.2 Bacterial Pathogens
  • 8.3 Fungal Pathogens
  • 8.4 Parasitic Pathogens
  • 8.5 Other Pathogen Types

9 Global Rapid Multiplex Infectious Disease Testing Market, By Application

  • 9.1 Respiratory Infection Testing
  • 9.2 Gastrointestinal Infection Testing
  • 9.3 Bloodstream Infection & Sepsis Testing
  • 9.4 Meningitis & Encephalitis Testing
  • 9.5 Sexually Transmitted Infection Testing
  • 9.6 Healthcare-Associated Infection Testing
  • 9.7 Other Applications

10 Global Rapid Multiplex Infectious Disease Testing Market, By End User

  • 10.1 Hospitals & Clinics
  • 10.2 Diagnostic & Reference Laboratories
  • 10.3 Point-of-Care & Urgent Care Centers
  • 10.4 Academic & Research Institutions
  • 10.5 Public Health Laboratories
  • 10.6 Other End Users

11 Global Rapid Multiplex Infectious Disease Testing Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 bioMerieux SA
  • 14.2 F. Hoffmann-La Roche Ltd.
  • 14.3 QIAGEN N.V.
  • 14.4 Danaher Corporation
  • 14.5 Abbott Laboratories
  • 14.6 Becton, Dickinson and Company
  • 14.7 DiaSorin S.p.A.
  • 14.8 QuidelOrtho Corporation
  • 14.9 Thermo Fisher Scientific Inc.
  • 14.10 Seegene Inc.
  • 14.11 Hologic, Inc.
  • 14.12 Revvity, Inc.
  • 14.13 Applied BioCode, Inc.
  • 14.14 Molbio Diagnostics Pvt. Ltd.
  • 14.15 Bosch Healthcare Solutions GmbH
  • 14.16 Mobidiag Oy
  • 14.17 GenMark Diagnostics, Inc.
  • 14.18 Co-Diagnostics, Inc.
Product Code: SMRC41811

List of Tables

  • Table 1 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Product & Service (2023-2034) ($MN)
  • Table 3 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Instruments & Analyzers (2023-2034) ($MN)
  • Table 4 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Assay Kits & Reagents (2023-2034) ($MN)
  • Table 5 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Multiplex Test Panels (2023-2034) ($MN)
  • Table 6 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Sample Preparation & Extraction Reagents (2023-2034) ($MN)
  • Table 7 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Consumables & Cartridges (2023-2034) ($MN)
  • Table 8 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Testing Services (2023-2034) ($MN)
  • Table 9 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Other Products & Services (2023-2034) ($MN)
  • Table 10 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 11 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Syndromic Multiplex Panels (2023-2034) ($MN)
  • Table 12 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Targeted Multiplex Panels (2023-2034) ($MN)
  • Table 13 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 14 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 15 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Multiplex Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 16 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Isothermal Nucleic Acid Amplification (2023-2034) ($MN)
  • Table 17 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Microarray-Based Detection (2023-2034) ($MN)
  • Table 18 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Multiplex Immunoassays (2023-2034) ($MN)
  • Table 19 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 20 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Pathogen Type (2023-2034) ($MN)
  • Table 21 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Viral Pathogens (2023-2034) ($MN)
  • Table 22 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Bacterial Pathogens (2023-2034) ($MN)
  • Table 23 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Fungal Pathogens (2023-2034) ($MN)
  • Table 24 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Parasitic Pathogens (2023-2034) ($MN)
  • Table 25 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Other Pathogen Types (2023-2034) ($MN)
  • Table 26 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Application (2023-2034) ($MN)
  • Table 27 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Respiratory Infection Testing (2023-2034) ($MN)
  • Table 28 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Gastrointestinal Infection Testing (2023-2034) ($MN)
  • Table 29 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Bloodstream Infection & Sepsis Testing (2023-2034) ($MN)
  • Table 30 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Meningitis & Encephalitis Testing (2023-2034) ($MN)
  • Table 31 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Sexually Transmitted Infection Testing (2023-2034) ($MN)
  • Table 32 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Healthcare-Associated Infection Testing (2023-2034) ($MN)
  • Table 33 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 34 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 36 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Diagnostic & Reference Laboratories (2023-2034) ($MN)
  • Table 37 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Point-of-Care & Urgent Care Centers (2023-2034) ($MN)
  • Table 38 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Academic & Research Institutions (2023-2034) ($MN)
  • Table 39 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Public Health Laboratories (2023-2034) ($MN)
  • Table 40 Global Rapid Multiplex Infectious Disease Testing Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!